Pub. Date : 2021
PMID : 33994796
2 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. | Crizotinib | ROS proto-oncogene 1, receptor tyrosine kinase | Homo sapiens |
| 2 | Background: Crizotinib inhibits ALK, MET and ROS1 tyrosine kinases but the development of resistance to monotherapy is an issue. | Crizotinib | ROS proto-oncogene 1, receptor tyrosine kinase | Homo sapiens |